357669-64-8

Upstream product

• 357669-69-3 (4R,5R)-5-[N-benzyl-N-(2-oxo-2-phenylethyl)carbamoyl]-2,2-dimethyl[1,3]dioxolane-4-carboxylic acid methyl ester 
• 67812-33-3 (4R,5R)-5-(methoxycarbonyl)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid 
• 31410-16-9 2-benzylamino-1-phenyl-1-ethanone hydrobromide 
• 70-11-1 α-bromoacetophenone 
• 100-46-9 benzylamine 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO NEUROTROPHINES

The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and/or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the neurotrophine functions are involved in defect, particularly of Nerve Growth Factor (NGF), such as neurodegenerative diseases of central nervous system (CNS), acquired immundeficiency due to a reduced NGF biodisponibility, or morbous conditions in which the stimulus of neoangiogenesis process is convenient.

Synthesis of a new enantiopure bicyclic γ/δ-amino acid (BTKa) derived from tartaric acid and α-amino acetophenone

The synthesis of a novel enantiopure γ/δ-amino acid having the 3-aza-6,8-dioxabicyclo[3.2.1]octane structure was realized by the combination of tartaric acid derivatives and α-amino acetophenone followed by a trans-acetalisation process. This amino acid,